George Adam D. 4
4 · GW PHARMACEUTICALS PLC · Filed Jan 20, 2021
Insider Transaction Report
Form 4
George Adam D.
Secretary
Transactions
- Exercise/Conversion
Ordinary Shares
2021-01-15$10.61/sh+25,716$272,847→ 35,716 total - Exercise/Conversion
Share Options
2021-01-15−1,584→ 48,888 totalExercise: $9.61From: 2020-12-31Exp: 2028-02-26→ Ordinary Shares (1,584 underlying) - Exercise/Conversion
Ordinary Shares
2021-01-15$9.81/sh+52,560$515,614→ 88,276 total - Sale
Ordinary Shares
2021-01-15$11.72/sh−53,376$625,567→ 36,484 total - Sale
Ordinary Shares
2021-01-15$11.75/sh−26,484$311,187→ 10,000 total - Exercise/Conversion
Share Options
2021-01-15−52,560→ 0 totalExercise: $9.81From: 2020-01-06Exp: 2027-01-06→ Ordinary Shares (52,560 underlying) - Exercise/Conversion
Ordinary Shares
2021-01-15$9.61/sh+1,584$15,222→ 89,860 total - Exercise/Conversion
Ordinary Shares
2021-01-19$9.61/sh+9,600$92,256→ 19,600 total - Exercise/Conversion
Share Options
2021-01-15−25,716→ 4 totalExercise: $10.61From: 2018-06-24Exp: 2025-06-24→ Ordinary Shares (25,716 underlying) - Exercise/Conversion
Share Options
2021-01-15−9,600→ 39,288 totalExercise: $9.61From: 2020-12-31Exp: 2028-02-26→ Ordinary Shares (9,600 underlying) - Sale
Ordinary Shares
2021-01-19$11.68/sh−9,600$112,128→ 10,000 total
Footnotes (7)
- [F1]Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares of ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer.
- [F2]The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020.
- [F3]Represented by ADSs.
- [F4]Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($140.67 per ADS). These shares were sold in multiple transactions at prices ranging from $140.00 per ADS (or $11.67 per ordinary share) to $140.87 per ADS (or $11.74 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($141.04 per ADS). These shares were sold in multiple transactions at prices ranging from $141.11 per ADS (or $11.76 per ordinary share) to $141.61 per ADS (or $11.80 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($140.15 per ADS). These shares were sold in multiple transactions at prices ranging from $140.04 per ADS (or $11.67 per ordinary share) to $140.83 per ADS (or $11.74 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F7]Accelerated due to retirement of the reporting person.